Albert Labs International Corp (CSE:ABRT) announced it has filed a provisional patent application in the US covering its proprietary cultivation process for the production of Psilocybe mycelia and other types of fungi.
The research and drug development company has developed a process that it says can significantly boost the production volumes of psilocybin medicine.
In a statement, Vancouver-based Albert Labs said it sees the demand for naturally produced psilocybin “continuing to increase as the unmet needs for mental health treatment hit crisis levels worldwide.”
READ: Albert Labs says its shares have commenced trading on the Canadian Securities Exchange after closing reverse take-over transaction
CEO Michael Raymont called the announcement “a testament to the R&D (research and development) and engineering expertise on the Albert Labs team."
“Albert Labs' manufacturing technology breakthrough represents a very significant step forward in our production capabilities for pharmaceutical-quality psilocybin with consistent and standardized psychoactive properties,” Raymont told investors.
The CEO added that active pharmaceutical ingredient (API) consistency is “critically important” for regulatory approval, leaving many ‘field grown’ natural substances too variable for pharmaceutical usage.
“While a massive body of science dating back many centuries suggests that natural products can have major medicinal benefits, ‘crop-to-crop’ variability has been a severe drawback for their use in regulated pharmaceuticals for many decades,” Raymont added. “Using this new Albert Labs' technology, the consistent quality of our API is a significant step forward to delivering our first trial drug, KRN-101, to patients and thus to treating suffers with unmet mental health needs."
The new process and methodology optimized key parameters necessary to efficiently cultivate Psilocybe mycelia, resulting in an increased high-quality yield. It is not a synthetic or biosynthetic process, and does not use or introduce harmful synthetic chemicals or genetically modified bacteria in the production of psilocybin.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas